natgillin/translations-raw huggingface dataset:
Lung oedema, stridor
edem pluća,
Lung oedema, stridor
edem pluća, stridor
Lung or chest infections such as bronchitis or pneumonia
infekcije dišnog sustava kao što su bronhitis ili upala pluća
Lung problems
Plućne tegobe
Lung problems (such as oedema)
tegobe s plućima (poput edema)
Lung problems including blood clot in the lungs
Problemi s plućima uključujući krvni ugrušak u plućima
Lung problems, including a history of shortness of breath at rest or with activity (dyspnoea)
Problemi s plućima, uključujući povijest nedostatka zraka u mirovanju ili tijekom aktivnosti (dispneja)
Lung transplantation
Transplantacija pluća
lungs do not function as they should, causing breathlessness (respiratory failure)
pluća ne funkcioniraju kako bi trebala što uzrokuje zadihanost (zatajenje disanja)
lungs do not function as they should, causing breathlessness (respiratory failure)
pluća ne funkcioniraju kako bi trebala, što uzrokuje nedostatak zraka (respiratorno zatajenje)
lungs do not function as they should, causing breathlessness (respiratory failure)
pluća ne funkcioniraju kao što bi trebala, uzrokujući nedostatak zraka (respiratorno zatajenje)
Lungs1
Pluća1
Lungworms
Plućni crvi
Lungworms:
Plućni crvi:
lupus (immune/connective tissue disease) symptoms (joint pain, skin rashes, photosensitivity and fever)
imptomi lupusa (bolesti imunog/vezivnog tkiva) (bol u zglobovima, kožni osip, fotoosjetljivost i vrućica)
lupus (rare).
lupus (rijetko).
lupus-like syndrome
sindrom sličan lupusu1)
lupus-like syndrome1)
sindrom sličan lupusu1)
lurasidone
lurasidon
Lurasidone acts mainly by blocking the receptors for the neurotransmitters dopamine, 5- hydroxytryptamine (also called serotonin) and noradrenaline.
Lurasidon djeluje uglavnom blokirajući receptore za neurotransmitere dopamina, 5-hidroksitriptamina (naziva se također i serotonin) i noradrenalina.
Lurasidone also exhibits partial agonism at the 5HT-1A receptor with a binding affinity of 6.38 nM.
Lurasidon također pokazuje djelomični agonizam na 5HT-1A receptore s afinitetom vezanja od 6,38 nM.
Lurasidone and its active metabolite ID-14283 both contribute to the pharmacodynamic effect at the dopaminergic and serotonergic receptors.
Lurasidon i njegov aktivni metabolit ID-14283 oboje pridonose farmakodinamičkom djelovanju putem dopaminergijskih i serotoninergičkih receptora.
Lurasidone binds strongly to dopaminergic D2- and to serotonergic 5-HT2A and 5-HT7- receptors with high binding affinity of 0.994, 0.47 and 0.495 nM, respectively.
Lurasidon se veže snažno na dopaminske D2- i serotoninske 5-HT2A i 5-HT7-receptore s visokim afinitetom vezanja od 0,994; 0,47; odnosno 0,495 nM.
Lurasidone does not bind to histaminergic or muscarinic receptors.
Lurasidon se ne vezuje na histaminergičke ili muskarinske receptore.
Lurasidone dose (b) (c)
Doza lurasidona (b) (c)
Lurasidone doses of 37, 74, 111 and 148 mg are equivalent to 40, 80, 120 and 160 mg amounts of lurasidone hydrochloride.
Doze lurasidona od 37, 74, 111 i 148 mg odgovaraju količini od 40, 80, 120 i 160 mg lurasidonklorida.
Lurasidone doses ranging from 9 to 74 mg (10-80 mg lurasidone hydrochloride) administered to healthy subjects produced a dose-dependent reduction in the binding of 11C-raclopride, a D2/D3 receptor ligand, in the caudate, putamen and ventral striatum detected by positron emission tomography.
Pozitronskom emisijskom tomografijom detektirano je da je lurasidon, primijenjen u dozama u rasponu od 9 do 74 mg (10-80 mg lurasidonklorida) u zdravih ispitanika, izazvao o dozi ovisno smanjenje vezanja 11C-rakloprida, liganda D2/D3 receptora, u kaudatumu, putamenu i ventralnom strijatumu.
Lurasidone doses, which varied across the five trials, ranged from 37 to 148 mg lurasidone (equivalent to 40-160 mg lurasidone hydrochloride) once daily.
Doze lurasidona, koje su varirale unutar pet ispitivanja, bile su u rasponu od 37 do 148 mg lurasidona (što odgovara 40-160 mg lurasidonklorida) jednom dnevno.
Lurasidone elevates prolactin levels due to antagonism of dopamine D2 receptors.
Lurasidon povećava razinu prolaktina zbog antagonističkog djelovanja na dopaminske D2 receptore.
Lurasidone had a small increase from baseline to Month 12 in body weight and body mass index (Mean (SD): 0.73 (3.36) kg and 0.28 (1.17) kg/m2, respectively) compared to quetiapine XR (1.23 (4.56) kg and 0.45 (1.63) kg/m2, respectively).
Lurasidon je imao u Mjesecu 12, u odnosu na početnu vrijednost, mali porast tjelesne težine i indeksa tjelesne mase (srednja vrijednost (SD): 0,73 (3,36) kg, odnosno 0,28 (1,17) kg/m2) u usporedbi s kvetiapinom XR (1,23 (4,56) kg, odnosno 0,45 (1,63) kg/m2).
Lurasidone is contraindicated with strong CYP3A4 inducers (e.g. carbamazepine, phenobarbital, phenytoin, rifampicin, St John’s wort (Hypericum perforatum)) (see section 4.3).
Lurasidon je kontraindiciran s jakim CYP3A4 induktorima (npr. karbamazepin, fenobarbital, fenitoin, rifampicin, gospina trava (Hypericum perforatum)) (vidjeti dio 4.3).
Lurasidone was non-inferior to quetiapine XR in time to relapse of schizophrenia.
Lurasidon nije bio inferioran kvetiapinu XR u vremenu relapsa shizofrenije.
Lurasidone was not teratogenic in rats or rabbits at an exposure similar to or below the maximum recommended human dose (148 mg lurasidone equivalent to 160 mg lurasidone hydrochloride).
Lurasidon nije bio teratogen u štakora ili kunića prilikom izloženosti dozi sličnoj ili onoj ispod maksimalne preporučene doze za ljude (148 mg lurasidona, što odgovara 160 mg lurasidonklorida).
lurred speech
nerazgovijetan govor
Luteal phase support may be considered since lack of substances with luteotrophic activity (LH/hCG) after ovulation may lead to premature failure of the corpus luteum.
Može se razmotriti i podržavanje luteinske faze budući da manjak tvari s luteotropnim djelovanjem (LH/hCG) nakon ovulacije može dovesti do preranog propadanja žutog tijela.
luteinizing hormone (LH)
hormona (LH) i
Luteinizing Hormone (LH), Follicle Stimulating Hormone (FSH) and progesterone.
luteinizirajućeg hormona (LH), folikulostimulirajućeg hormona (FSH) niti
Lutetium (177Lu) also emits low-energy γ-rays which allow scintigraphic, biodistribution and dosimetry studies with the same Lutetium (177Lu)-labelled medicinal products.
Lutecij (177Lu) također emitira γ-zrake niske energije što omogućuje scintigrafijska, biodistribucijska i dozimetrijska ispitivanja s istim lijekovima označenim lutecijem (177Lu).
Lutetium (177Lu) chloride distributes mainly tothe liver, spleen and bone.
Lutecijev (177Lu) klorid uglavnom se distribuira u jetru, slezenu i kosti.
Lutetium (177Lu) chloride is produced by irradiation of 176Lu with neutrons.
Lutecijev (177Lu) klorid nastaje iradijacijom 176Lu s neutronima.
Lutetium (177Lu) decays by emission of beta radiation to stable Hafnium (177Hf).
Lutecij (177Lu) se emisijom beta zračenja raspada u stabilni hafnij (177Hf).
Lutetium (177Lu) emits both medium-energy beta particles and imageable gamma photons, and has a half-life of 6.647 days.
Lutecij (177Lu) emitira i beta čestice srednje energije i gama-fotone vidljive na snimci te mu je vrijeme poluraspada 6647 dana.
Lutetium (177Lu) emits β-particles of moderate maximum energy (0.498 MeV) with a maximum tissue penetration of approximately 2 mm.
Lutecij (177Lu) emitira β-čestice umjerene maksimalne energije (0,498 MeV) s maksimalnom penetracijom u tkivo od otprilike 2 mm.
Lutropin alfa is a recombinant human Luteinising Hormone (r-hLH), a glycoprotein composed of non- covalently bound α- and ß-subunits.
Lutropin alfa je rekombinantni humani luteinizirajući hormon (r-hLH), glikoprotein koji se sastoji od nekovalentno vezane alfa i beta podjedinice.
Lutropin alfa is recombinant human Luteinising Hormone (r-hLH), produced by recombinant DNA technology.
Lutropin alfa je rekombinantni humani luteinizirajući hormon (r-hLH) proizveden tehnologijom rekombinantne DNK.
Lutropin alfa shows linear pharmacokinetics, as assessed by AUC which is directly proportional to the dose administered.
Lutropin alfa pokazuje linearnu farmakokinetiku, procijenjeno prema AUC, što je izravno proporcionalno danoj dozi.
Luveris
Doza
Luveris 75 IU powder and solvent for solution for injection.
Luveris 75 IU prašak i otapalo za otopinu za injekciju.
Luveris 75 IU Powder for injection Lutropin alfa Subcutaneous use
Luveris 75 IU Prašak za injekciju lutropin alfa Potkožno
Luveris comes as a powder and solvent for solution for injection.
Luveris se isporučuje kao prašak i otapalo za otopinu za injekciju.
Luveris contains less than 1 mmol sodium (23 mg) per dose.
Luveris sadrži manje od 1 mmol (23 mg) natrija po dozi.
Luveris is a medicine containing lutropin alfa, a recombinant Luteinising Hormone (LH) which is essentially similar to the hormone found naturally in humans, but is made by means of biotechnology.
Luveris je lijek koji sadrži lutropin alfa, rekombinantni luteinizirajući hormon (LH) koji je u biti sličan hormonu koji se prirodno nalazi kod ljudi, ali se dobiva biotehnološkim postupkom.
Luveris is indicated for the stimulation of follicular development, in association with FSH (see section 4.1).
Luveris je indiciran za stimulaciju razvoja folikula u vezi s FSH (vidjeti dio 4.1).
Luveris is not for use in children and adolescents below 18 years old.
Luveris nije namijenjen za primjenu u djece i adolescenata mlađih od 18 godina.
Luveris is not indicated during breast-feeding.
Luveris nije indiciran tijekom dojenja.
Luveris is recommended for the treatment of adult women who have been shown to produce very low levels of some of the hormones involved in the natural reproductive cycle.
Luveris se preporučuje za liječenje odraslih žena kod kojih su nađene vrlo niske razine nekih hormona uključenih u prirodne cikluse reprodukcije.
Luxe mbourg/Luxemburg
Luxe mbourg/Luxe mburg
Luxe mbourg/Luxemburg s.a.
Luxe mbourg/Luxe mburg s.a.
Luxembourg/Luxemburg
Deutschland
Luxembourg/Luxemburg AstraZeneca S.A./N.V. Tél/Tel: +32 2 370 48 11
Тел.: +359 (2) 44 55 000 Tél/Tel: +32 2 370 48 11
Luxembourg/Luxemburg Eli Lilly Benelux S.A./N.V. Tél/Tel: + 32 (0)2 548 84 84
Luxembourg/Luxemburg Eli Lilly Benelux S.A./N.V. Tél/Tel: + 32 (0) 2 548 84 84
Luxembourg/Luxemburg GlaxoSmithKline Pharmaceutica Belgique/Belgien
Luxembourg/Luxemburg GlaxoSmithKline Pharmaceuticals s.a./n.v.
Luxembourg/Luxemburg GlaxoSmithKline Pharmaceuticals s.a./n.v.
Luxembourg /Luxemburg GlaxoSmithKline Pharmaceuticals s.a./n.v.
Luxembourg/Luxemburg HRA Pharma Benelux Tél/Tel: +32 2 709 22 95
Luxembourg/Luxemburg HRA Pharma Benelux Tél/Tel: + 32 2 709 22 95
Luxembourg/Luxemburg MERCK NV/SA, Belgique/Belgien Tél/Tel: +32 2 686 07 11
Luxembourg/Luxemburg, MERCK NV/SA, Belgique/Belgien Tél/Tel: +32 2 686 07 11
Luxembourg/Luxemburg MSD Belgium BVBA/SPRL Tél/Tel : +32 (0)2 776 62 11 dpoc_belux@merck.com
Luxembourg/Luxemburg MSD Belgium BVBA/SPRL Tél/Tel :+32 (0)2 776 62 11 dpoc_belux@merck.com
Luxembourg/Luxemburg MSD Belgium BVBA/SPRL Tél/Tel : 0800 38 693
Luxembourg/Luxemburg MSD Belgium BVBA/SPRL Tél/Tel: 0800 38 693
Luxembourg/Luxemburg Orphan Europe Benelux Tél/Tel: +32 2 46101 36
Luxembourg/Luxemburg Orphan Europe Benelux Tel: +32 2 46101 36
Luxembourg/Luxemburg ratiopharm GmbH Allemagne/Deutschland Tél: +49 731 402 02
Luxembourg/Luxemburg ratiopharm GmbH Allemagne/Deutschland Tel: +49 731 402 02
Luxembourg/Luxemburg ratiopharm GmbH Allemagne/Deutschland Tél: +49 731 402 02
Österreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43(0)1 970070
Luxembourg/Luxemburg s.a.
Luxe mbourg/Luxe mburg s.a.
Luxembourg/Luxemburg s.a.
Luxembourg/Luxemburg
LV 400 mg/m2 intravenously over 30 minutes, followed by 5-FU 2,400 mg/m2 intravenously over 46 hours, administered every 2 weeks.
LV 400 mg/m2 intravenski tijekom 30 minuta, a potom 5-FU 2400 mg/m2 intravenski tijekom 46 sati, primijenjeno svaka 2 tjedna.
LV dose does not require adjustment.
Dozu LV nije potrebno prilagođavati.
LVEF 40% to
LVEF 40% do
LVEF = Left ventricular ejection fraction
LVEF = ejekcijska frakcija lijeve klijetke
LVEF decrease
smanjenje LVEF
LVEF has not
unutar 10 postotnih
LVEF<35% or NYHA>=class I
LVEF<35% ili NYHA stupanj >=I
LVL
METAVIR
LVL (≤600,000
24,7; 33,8
LVL (≤600,000
56,1 (157/280) 48,4; 63,7
Lymph node pain
bol u limfnom čvoru
lymph node pain and swollen lymph nodes
bol u limfnom čvoru i otečeni limfni čvorovi
Lymph node pain Eosinophilia Lymphadenopathy
bol u limfnom čvoru eozinofilija limfadenopatija
lymph node pain; low count of white blood cells that fight infection; swollen glands in the neck, armpit and groin
bol u limfnim čvorovima, snižen broj bijelih krvnih stanica koje se bore protiv infekcije; otečene žlijezde na vratu, pazuhu i preponama
Lymphadenitis
Limfadenitis
Lymphadenitis, Regional lymphadenopathy, Thrombocytopenia
limfadenitis, regionalna limfadenopatija, trombocitopenija
Lymphadenopathy (cervical, axillary)
limfadenopatija (vratni, pazušni)
Lymphadenopathy (N)
limfadenopatija (N)
Lymphadenopathy of peripheral nodes was noted in all groups, increasing in frequency with increasing dose, and was frequently associated with interdigital furunculosis.
Limfadenopatija perifernih čvorova je uočena u svim grupama, učestalost se povećava sa povećanjem doze, i često je povezana sa interdigitalnim furunkulozama.
lymphadenopathy, lymphopaenia
limfadenopatija, limfopenija
lymphadenopathy, splenic infarction
limfadenopatija, infarkt slezene
Lymphadenopathy2, thrombocytopenia2
limfadenopatija2 , trombocitopenija2
Lymphadenopathyc
Limfadenopatijac
Lymphadenopathy†
Limfadenopatija
Lymphangitis
limfangitis
lymphatic
krvi i
lymphatic obstruction
začepljenje limfnih zila
lymphatic obstruction
začepljenje limfnih žila
lymphatic system
krvi i limfnog sustava
lymphatic system
limfnog sustava
lymphatic system disorders
Poremećaji krvi i limfnog sustava
Lymphocyte count
Broj limfocita
Lymphocyte count decreased
niženi broj limfocita
Lymphocyte count decreased
Smanjen broj limfocita
Lymphocyte count decreased
Snižen broj limfocita
Lymphocyte count decreased (<1,500/mm³) 
Smanjeni broj limfocita (< 1500/mm3) x ^ o
Lymphocyte count decreased (NB)
smanjen broj limfocita (NB)
lymphocyte count decreased, white blood cell count decreased, neutrophil count decreased, hematocrit decreased, blood potassium increased, blood urea nitrogen increased
manjenje broja limfocita, smanjenje broja bijelih krvnih stanica, smanjenje broja neutrofila, snižen hematokrit, povećanje kalija u krvi, povećanje razine dušika iz ureje u krvi
Lymphocyte counts progressively return to normal range within 1-2 months of stopping therapy (see section 5.1).
Broj limfocita progresivno se vraća u normalni raspon u roku od 1 do 2 mjeseca nakon prekida terapije (vidjeti dio 5.1).
Lymphocytosis: Laboratory tests may show an increase in white blood cells (called “lymphocytes”) in your blood in the first few weeks of treatment.
Limfocitoza: laboratorijske pretrage mogu pokazati povišenje bijelih krvnih stanica (zvanih “limfociti”) u krvi u prvim tjednima liječenja.
Lymphoedema
limfedem
Lymphoedema (G3/4: 0%)
limfedem (G3/4: 0%)
Lymphoedemaa
limfedema
Lymphoid
ubrzanje
Lymphoid blast phase and
Mijeloidna blastna kriza (n= 74)c
Lymphoid tissue (e.g., tonsillar) hypertrophy associated with complications, such as snoring, sleep apnoea, and chronic middle-ear effusions have been reported with the use of INCRELEX.
Za vrijeme korištenja INCRELEXA prijavljena je hipertrofija limfoidnog tkiva (npr. tonzilarnog) povezana s komplikacijama, kao što su hrkanje, apneja za vrijeme spavanja i kronični izljevi u srednjem uhu.
LYMPHOMA
LINFOM
Lymphoma was diagnosed in 9 subjects (1 in the golimumab 50 mg treatment groups and 8 in the golimumab 100 mg treatment groups) with an incidence (95% CI) per 100 subject-years of follow-up of 0.03 (0.00, 0.16) and 0.12 (0.05, 0.24) events for golimumab 50 mg and 100 mg respectively and 0.00 (0.00, 0.59) events for the placebo.
Limfom je dijagnosticiran u 11 ispitanika (1 iz skupine liječene golimumabom u dozi od 50 mg i 10 u skupini liječenoj golimumabom u dozi od 100 mg) s incidencijom (95% CI) na 100 ispitanik-godina praćenja od 0,03 (0,00; 0,15) događaja te 0,13 (0,06; 0,24) za golimumab u dozi od 50 mg i 100 mg, a 0,00 (0,00; 0,57) događaja za placebo.
Lymphoma was reported in 1 patient, non-melanoma skin cancer in 2 patients, and other malignancies in 5 patients.
Limfom je prijavljen u 1 bolesnika, nemelanomski rak kože u 2, a druge zloćudne bolesti u njih 5.
lymphoma**,
limfom**,
Lymphoma*; Post transplant lympho- proliferative disorder
limfom*/post- transplantacijski limfoprolifera- tivni poremećaj
Lymphoma: there have been reports of individual cases of lymphoma which subsided in a number of cases once treatment with methotrexate had been discontinued.
Limfom: zabilježeni su pojedinačni slučajevi limfoma koji se u velikom broju slučajeva povukao nakon prestanka liječenja metotreksatom.
Lymphopaenia
limfopenija
Lymphopenia (5.7%) (G3/4: 2.1%)
Često (učestalost %)
Lymphopenia includes lymphopenia and decreased lymphocyte count. b: Hypomagnesaemia includes hypomagnesaemia and decreased blood magnesium.
Limfopenija uključuje limfopeniju i smanjeni broj limfocita. b: Hipomagnezemija uključuje hipomagnezemiju i sniženi magnezij u krvi.
Lymphopenia includes lymphopenia and lymphocyte count decreased. b: Hypomagnesaemia includes hypomagnesaemia and blood magnesium decreased.
Limfopenija uključuje limfopeniju i smanjeni broj limfocita. b: Hipomagnezemija uključuje hipomagnezemiju i sniženi magnezij u krvi.
Lymphopenia, leukopenia
limfopenija, leukopenija
Lymphopenia, petechiae
limfopenija, petehije
Lymphopeniaa
limfopenijaa
Lymphopeniab
Limfopeni jab
Lymphopeniac
Limfopenijac
Lymphopoenia
limfopenija
Lymphoproliferative disease or lymphoma developed in 0.6% of patients receiving CellCept (2 g or 3 g daily) in combination with other immunosuppressants in controlled clinical trials of renal (2 g data), cardiac and hepatic transplant patients followed for at least 1 year.
U kontroliranim kliničkim ispitivanjima bolesnika s presađenim bubregom (podaci o dozi od 2 g), srcem ili jetrom praćenima barem jednu godinu, kod 0,6% bolesnika koji su primali CellCept (2 g ili 3 g dnevno) u kombinaciji s drugim imunosupresivima došlo je do razvoja limfoproliferativne bolesti ili limfoma.
Lymphoproliferative disease or lymphoma developed in 0.6% of patients receiving CellCept (2 g or 3 g daily) in combination with other immunosuppressants in controlled clinical trials of renal (2 g data), cardiac and hepatic transplant patients followed for at least 1 year.
U kontroliranim kliničkim ispitivanjima bolesnika s presađenim bubregom (podaci o dozi od 2 g), srcem ili jetrom praćenima barem jednu godinu, kod 0,6% bolesnika koji su primali CellCept (2 g ili 3 g dnevno) u kombinaciji s drugim imunosupresivima, došlo je do razvoja limfoproliferativne bolesti ili limfoma.
Lymphoproliferative disease or lymphoma developed in 0.6% of patients receiving mycophenolate mofetil (2°g or 3°g daily) in combination with other immunosuppressants in controlled clinical trials of renal (2°g data), cardiac and hepatic transplant patients followed for at least 1°year.
U kontroliranim kliničkim ispitivanjima bolesnika s presađenim bubregom (podaci o dozi od 2 g), srcem ili jetrom praćenima barem jednu godinu, kod 0,6 % bolesnika koji su primali mofetilmikofenolat (2 g ili 3 g dnevno) u kombinaciji s drugim imunosupresivima, došlo je do razvoja limfoproliferativne bolesti ili limfoma.
lymphoproliferative disorders treatment with Xaluprine increases your risk of getting a type of cancer called lymphoproliferative disorder.
limfoproliferativnih poremećaja liječenje Xaluprineom povećava rizik od dobivanja vrste raka koji se naziva limfoproliferativni poremećaj.
Lymphoseek 50 micrograms kit for radiopharmaceutical preparation
Lymphoseek 50 mikrograma set za pripravu radiofarmaceutika
Lymphoseek 50 micrograms kit for radiopharmaceutical preparation Tilmanocept
Lymphoseek 50 mikrograma set za pripravu radiofarmaceutika tilmanocept
Lymphoseek 50 micrograms solution for injection technetium (99mTc) tilmanocept
Lymphoseek 50 mikrograma otopina za injekciju tehnecij (99mTc) tilmanocept
Lymphoseek contains sodium:
Lymphoseek sadrži natrij:
Lymphoseek is a receptor-targeted radiopharmaceutical that is designed to rapidly transit lymphatic vessels; it biotargets, accumulates, and is retained in primary, key predictive, draining lymph nodes (sentinel lymph nodes).
Lymphoseek je radiofarmaceutik usmjeren na receptor osmišljen kako bi brzo prolazio limfni sustav; on se ciljano veže, nakuplja i zadržava u primarnim, dijagnotički ključnim drenažnim limfnim čvorovima (limfni čvorovi čuvari).
Lymphoseek is injected under the skin, under the nipple, or in or around the tumour.
Lymphoseek se ubrizgava ispod kože, ispod bradavice, ili u tumor ili oko njega.
Lynparza can be administered in patients with mild renal impairment (creatinine clearance 51 to 80 ml/min) with no dose adjustment.
Lynparza se može davati bolesnicama s blagim oštećenjem bubrežne funkcije (klirens kreatinina 51 do 80 ml/min) bez prilagodbe doze.
Lynparza dose adjustment is recommended for patients with moderate renal impairment (see section 4.2).
Kod bolesnica sa umjerenim oštećenjem bubrežne funkcije preporučuje se prilagodba doze lijeka Lynparza (vidjeti dio 4.2).
Lynparza hard capsules contain the active substance olaparib.
Lynparza tvrde kapsule sadrže djelatnu tvar olaparib.
Lynparza has been shown to increase the time patients live without their disease getting worse in one main study involving 265 patients.
U jednom glavnom ispitivanju utvrđeno je kako lijek Lynparza produljuje vrijeme tijekom kojeg su bolesnice živjele bez pogoršanja bolesti.
Lynparza is a cancer medicine used for the ‘maintenance’ treatment of adult patients with high grade serous epithelial cancer of the ovary (a type of advanced cancer of the ovary), including cancer of the fallopian tubes (part of the female reproductive system that connect the ovaries to the uterus) and cancer of the peritoneum (the membrane lining the abdomen).
Lynparza je citostatatik za terapiju održavanja kod odraslih bolesnica epitelnim karcinomom jajnika visokog stupnja (tip uznapredovanog raka jajnika) uključujući karcinom jajovoda (dio ženskog reproduktivnog sustava koji povezuje jajnike s maternicom) i karcinomom peritoneuma (membranske ovojnice abdomena).
Lynparza is a potent inhibitor of human poly (ADP-ribose) polymerase enzymes (PARP-1, PARP-2, and PARP-3), and has been shown to inhibit the growth of selected tumour cell lines in vitro and tumour growth in vivo either as a standalone treatment or in combination with established chemotherapies.
Lynparza je snažan inhibitor enzima humane poli (ADP-riboza) polimeraze (PARP-1, PARP-2, i PARP-3) te se pokazalo da inhibira rast odabranih tumorskih staničnih linija in vitro i rast tumora in vivo kada se koristi u monoterapiji ili u kombinaciji s utvrđenim kemoterapijama.
Lynparza is a white, opaque, hard capsule, marked with “OLAPARIB 50 mg” and the AstraZeneca logo in black ink.
Lynparza je bijela, neprozirna tvrda kapsula s oznakom "OLAPARIB 50 mg" i logom tvrtke AstraZeneca otisnutima crnom tintom.
Lynparza is available as capsules (50 mg) to be taken by mouth.
Lynparza je lijek dostupan u kapsulama (50 mg) i uzima se kroz usta.
Lynparza is given after treatment with platinum-based medicines, when the tumour is diminishing in size or has completely disappeared.
Lynparza se primjenjuje nakon liječenja lijekovima temeljenima na platini nakon što se smanji veličina tumora ili tumor u potpunosti nestane.
Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
Lynparza je indicirana kao monoterapija za terapiju održavanja kod odraslih bolesnica s recidivom na platinu osjetljivog seroznog epitelnog karcinoma jajnika visokog stupnja nediferenciranosti, karcinoma jajovoda ili primarnog peritonealnog karcinoma s mutacijom (germinativnom i/ili somatskom) BRCA gena koje su ostvarile odgovor (potpun ili djelomičan) na kemoterapiju temeljenu na platini.